These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16526947)

  • 1. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense therapy in clinical oncology: preclinical and clinical experiences.
    Tamm I; Wagner M
    Mol Biotechnol; 2006 Jul; 33(3):221-38. PubMed ID: 16946452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Kim R; Emi M; Tanabe K; Toge T
    Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
    Hau P; Jachimczak P; Bogdahn U
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1663-74. PubMed ID: 19895249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides as therapeutic agents.
    Galderisi U; Cascino A; Giordano A
    J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotides strategy in the treatment of hypertension.
    Kagiyama S; Kagiyama T; Phillips MI
    Curr Opin Mol Ther; 2001 Jun; 3(3):258-64. PubMed ID: 11497350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense therapy of hematologic malignancies.
    Cotter FE
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):9-14. PubMed ID: 10530711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.